The Food and Drug Administration on Friday approved Pfizer's treatment for a rare genetic bleeding disorder, making it the company's first-ever gene therapy to win clearance in the U.S. The agency greenlit the drug, which will be marketed as Beqvez, for adults with moderate to severe hemophilia B who meet certain requirements.More than 7,000 people in the U.S. are living with the debilitating condition, according to an advocacy group. The condition is caused by insufficient levels of a certain protein that ...

These two pharma stocks have followed distinct paths of late. Which is the better investment?The pharmaceutical industry has been a whirlwind of highs and lows for investors over the past two decades. The high-risk, high-reward nature of drug development, coupled with the cyclical pattern of new drug launches and patent expirations, has seemingly lost its allure for many investors over the past 20 years.However, amid this challenging landscape, some early stage biotech firms have still managed to deliver li ...

股价表现 - 辉瑞公司最新收盘价为26.26美元，较前一交易日上涨了1%[1] - 辉瑞公司股票在过去一个月中下跌了4.97%，医药行业下跌了6.67%，标普500指数下跌了3.97%[2] 财务表现 - 辉瑞公司将于2024年5月1日发布财报，预计每股收益为0.56美元，较去年同期下降了54.47%[3] - 辉瑞公司当前的Zacks共识估计预测收入为138.6亿美元，较去年同期下降了24.21%[4]

CatEyePerspectiveIntroduction: A biotech stock with a large dividend is pretty uncommon since biotechnology and pharmaceutical companies tend to focus more on reinvestment into pipeline growth rather than shareholder returns. But as a biopharma grows larger and there may be a paucity of potential pipeline or partnership opportunities that may be worth investing in, the company may look to return some of its profits to its investors through either dividends or share repurchases. Pfizer (NYSE:PFE) seems t ...

股价表现 - 辉瑞公司（Pfizer）股价在最新交易日收盘时为25.91美元，较前一交易日上涨了0.19%[1] - 辉瑞公司股价表现优于标普500指数，而标普500指数当日下跌了1.2%[1] - 辉瑞公司股价在过去一个月中下跌了7.44%，落后于医药行业的6.57%和标普500指数的0.85%[2] 财报预测 - 投资者将密切关注辉瑞公司即将发布的财报，预计公司将在2024年5月1日公布财报，预计每股收益为0.56美元，同比下降了54.47%[3] - 辉瑞公司整个财年的Zacks共识预测显示，每股收益为2.22美元，营收为599.9亿美元，分别较去年增长了20.65%和2.56%[4] 公司评级与估值 - 辉瑞公司目前的Zacks排名为3（持有），预计每股收益在过去30天内上升了0.18%[7] - 辉瑞公司目前的前瞻市盈率为11.66，低于行业平均前瞻市盈率13.84[8] - 辉瑞公司的PEG比率为1.16，略高于大型医药公司行业的平均PEG比率1.69[9] 行业排名 - 大型医药公司行业属于医疗行业，目前Zacks行业排名为202，位于所有行业中的后20%[10] - Zacks行业排名评估了各行业群体的实力，研究表明，排名前50%的行业的表现是排名后50%的两倍[11]

公司财务状况 - 辉瑞公司负债高达753亿美元，利息支出将持续拖累盈利增长[5] - 公司计划通过内部再投资和股东回报等方式平衡资本分配，未来有望实现更好的财务表现[10] - 辉瑞目前的股息率高达6.3%，随着公司战略计划的推进，股息率有望进一步提升[11] 公司业务展望 - 公司过去的成功主要来自于冠状病毒疫苗，但随着需求下降，未来难以再现这样的成功[6] - 辉瑞公司在癌症药物研发领域有着广泛布局，未来有望推出多款有望成为“亿万美元药物”的药品[9] - 尽管需要等待几年新的收入来源成熟，但现在是购买辉瑞股票的绝佳时机，公司有着长期稳定的商业化成功记录[12] 公司股价表现 - 辉瑞目前面临着股价下跌、营收增长乏力和净利润下滑等问题[4] - 辉瑞公司目前处于低谷，但未来前景光明[8]

J Studios Investment Thesis I think it is safe to say that Pfizer Inc. (NYSE:PFE) is probably one of the least wanted stocks, not only in the pharmaceutical complex of stocks but in the broader view of the market. Pfizer has been plagued by a myriad of issues that are posing severe headwinds for the company since the world emerged from the pandemic, causing acute decelerations in the company's COVID-19 vaccine business. In addition, Pfizer has to deal with high costs across the board while building an innov ...

When something seems too good to be true it might not be.Pfizer (PFE 0.08%) stock is relatively cheap. I can easily back up that claim. The big drugmaker's shares trade at lower forward earnings multiples than the S&P 500 and the S&P 500 healthcare sector. That meets the definition of relatively cheap.However, I wouldn't go so far as to claim that Pfizer is the cheapest stock in the S&P 500. At least, I wouldn't have until I saw something recently that blew me away and prompted me to wonder if Pfizer just m ...

Alexandros Michailidis Investment thesis My previous bullish thesis about Pfizer Inc. (NYSE:PFE) from October 2023 did not age well, as the stock delivered a -10% total return over the last half-year, substantially lagging behind the broader market. Despite it, today I want to reiterate my bullish thesis because recent developments suggest that the business continues moving in line with its innovative approach and commitment to create value for shareholders. The market seems to be wrong by overreacting to 2 ...

辉瑞公司产品销售 - 辉瑞公司在新推出和新收购的产品上依赖，以改善销售业绩[1] - 辉瑞公司的COVID产品销售额下降，主要是由于需求下降[2] - 辉瑞公司预计未来几个季度非COVID产品的营收增长将更好，主要受到Prevnar、Vyndaqel和Eliquis等主要产品、Abrysvo、Penbraya和Zavzpret等新产品的推出以及从Seagen收购的产品的推动[3] 辉瑞公司新药批准 - 辉瑞公司去年在FDA获得了创纪录的九个新药物/疫苗批准，这些批准有望推动2024年及以后的增长[4] - 辉瑞公司的RSV疫苗Abrysvo已获批并在2023年在美国和欧盟推出，用于帮助保护老年人和婴儿，同时FDA还批准了其治疗中度至重度活动性溃疡性结肠炎的每日一次药丸Velsipity（etrasimod）以及其五价脑膜炎球菌疫苗Penbraya[5] - 辉瑞公司的JAK3抑制剂Litfulo和长效每周一次治疗儿童生长激素缺乏的Ngenla已获批，以及其他产品也在不同国家获得批准[6] 辉瑞公司新产品表现 - 辉瑞公司的新药Abrysvo RSV疫苗在2023年下半年销售超出管理层预期，预计2024年销售将继续强劲[7] - 辉瑞公司的新收购Seagen在2023年12月增加了一类抗体药物复合物（ADCs），Adcetris、Padcev、Tukysa和Tivdak，这些从Seagen收购的癌症药物也将在2024年提供顶线支持[8] - 辉瑞公司新收购的产品Nurtec ODT/Vydura和Oxbryta在过去两个季度中逐步改善，预计这种积极趋势将在2024年持续[9]